Brachyury peptide vaccine - GlobeImmune

Drug Profile

Brachyury peptide vaccine - GlobeImmune

Alternative Names: GI-6301; Yeast brachyury vaccine - GlobeImmune

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator GlobeImmune
  • Developer GlobeImmune; National Cancer Institute (USA)
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Germ cell and embryonal neoplasms
  • Phase I Solid tumours

Most Recent Events

  • 12 Sep 2016 Brachyury peptide vaccine is still in phase I trials for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT01519817)
  • 22 Apr 2015 Phase-II clinical trials in Germ cell cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (SC)
  • 16 Mar 2015 GlobeImmune plans a phase II trial for Chordoma (Unresectable) in USA (NCT02383498)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top